This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 2K7
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de TCR2 Therapeutics Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.49 |
| 52 Week High | US$6.05 |
| 52 Week Low | US$2.49 |
| Beta | 1.78 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -81.32% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 2K7 | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 0% | 2.1% | -1.0% |
| 1Y | n/a | -22.4% | 2.0% |
Rentabilidad vs. Industria: Insufficient data to determine how 2K7 performed against the German Biotechs industry.
Rentabilidad vs. Mercado: Insufficient data to determine how 2K7 performed against the German Market.
Volatilidad de los precios
| 2K7 volatility | |
|---|---|
| 2K7 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 2K7 has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine 2K7's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 139 | Garry Menzel | www.tcr2.com |
Resumen de fundamentos de TCR2 Therapeutics Inc.
| Estadísticas fundamentales de 2K7 | |
|---|---|
| Capitalización bursátil | €95.44m |
| Beneficios(TTM) | -€115.27m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.8x
Ratio precio-beneficio (PE)¿Está 2K7 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 2K7 | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$114.71m |
| Beneficios | -US$114.71m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.97 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado 2K7 a largo plazo?
Ver rendimiento histórico y comparativa